<DOC>
	<DOCNO>NCT00002401</DOCNO>
	<brief_summary>The purpose study see safe effective give delavirdine ( DLV ) combination two three drug HIV-infected patient . The drug use combination DLV zidovudine ( ZDV ) , indinavir ( IDV ) , lamivudine ( 3TC ) .</brief_summary>
	<brief_title>A Study Delavirdine Used Together With Other Anti-HIV Drugs HIV-Infected Patients</brief_title>
	<detailed_description>In open-label pilot study , patient randomize 1of follow 4 arm 24 week : Arm 1 ( 40 patient ) : DLV plus ZDV plus IDV . Arm 2 ( 40 patient ) : DLV plus IDV plus 3TC* . Arm 3 ( 40 patient ) : DLV plus ZDV plus IDV plus 3TC . Arm 4 ( 40 patient ) : ZDV plus IDV plus 3TC . - Dose determine body weight . Patients may opt continue study 24 additional week discretion investigator .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Delavirdine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<criteria>Inclusion Criteria Prior Medication : Allowed : Less 1 month prior treatment zidovudine . Exclusion Criteria Prior Medication : Excluded : Prior indinavir . Prior lamivudine . Prior protease inhibitor . Prior nonnucleoside reverse transcriptase inhibitor . 1 month prior zidovudine . 1 . HIV1 positive . CD4 coun ti 50 . HIV1 RNA level great 20,000 .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 1999</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Indinavir</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Delavirdine</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Viral Load</keyword>
</DOC>